Zejula Shows Ability to Treat Range of Advanced Ovarian Cancers in Phase 2 Trial

Zejula Shows Ability to Treat Range of Advanced Ovarian Cancers in Phase 2 Trial
Zejula (niraparib) showed an ability to treat people with recurrent and heavily treated ovarian cancer, particularly those with mutations in DNA repairing genes, results of a Phase 2 trial show. Tesaro’s Zejula is an orally active PARP inhibitor, a class of drugs used for treating cancer in some women who have mutations in BRCA genes. The treatment relies on the notion that cancers with BRCA mutations use other enzymes, like PARP, to repair their DNA. Inhibiting, or blocking, these 'backup' enzymes leads to an accumulation of mutations that is not sustainable, eventually killing cancer cells. While PARP inhibitors works best in BRCA-mutated cancers, there is scientific evidence that some cancers without BRCA mutations may also respond to this type of therapy. Tesaro is evaluating Zejula as a treatment of advanced ovarian and breast cancer in patients with and without BRCA mutations. The treatment is approved in the
Subscribe or to access all post and page content.